Mitoxantrone and G-CSF in Treating Patients With Metastatic Prostate Cancer
A Phase I/II Trial Using Weekly Mitoxantrone Chemotherapy and G-CSF for the Treatment of Metastatic Hormone Refractory Prostate Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing
so they stop growing or die. Combining chemotherapy with G-CSF may make tumor cells more
sensitive to the chemotherapy drug and may kill more tumor cells.
PURPOSE: Phase I/II trial to study the effectiveness of mitoxantrone plus G-CSF in treating
patients with metastatic prostate cancer that has not responded to hormone therapy.
OBJECTIVES: I. Study the effectiveness of mitoxantrone in patients with metastatic, hormone
refractory prostate cancer. II. Assess the side effects of mitoxantrone in this patient
population. III. Determine whether filgrastim (granulocyte colony-stimulating factor; G-CSF)
treatment can overcome chronic bone marrow suppression and facilitate a dose intensive
mitoxantrone chemotherapy regimen in this patient population.
OUTLINE: This is a dose escalation study. Patients receive a 30 minute intravenous infusion
of mitoxantrone once a week on day 1. On days 2-6 of each week, patients receive
subcutaneous filgrastim (granulocyte colony-stimulating factor; G-CSF). Treatment continues
for patients who respond to therapy and exhibit no disease progression. Dose escalation
proceeds until the maximum tolerated dose (MTD) of mitoxantrone with G-CSF support is
determined. The MTD is defined as the dose preceding that at which 2 or more patients
experience dose limiting toxicity. After the MTD is determined, an additional 20-40 patients
are enrolled at this dose level to examine their response to this therapy.
PROJECTED ACCRUAL: Approximately 12-24 patients will be accrued for the phase I portion of
this protocol. An additional 20-40 patients may be accrued for the phase II portion of this
adenocarcinoma of the prostate, stage IV prostate cancer, recurrent prostate cancer
National Cancer Institute (NCI)
Hope Cancer Institute, Inc.